BioCentury Innovations (formerly SciBX)
As published Thursday, January 22, 2015
With antibiotic discovery coming back into vogue, two groups have literally gone to ground to find new compounds produced by bacteria in the soil. Using designed-for-purpose screening systems, the teams identified two unknown antimicrobial peptides - teixobactin and lysocin E - that act at new membrane targets and have the potential to induce little or no resistance. But given the poor safety record for peptide antibiotics, the new approaches and targets might end up upstaging the compounds themselves in terms of importance for the field.
Teixobactin was discovered by researchers at Northeastern University in collaboration with NovoBiotic Pharmaceuticals LLC. Lysocin E was identified by a group at the University of Tokyo. Both teams are seeking partners to help advance the compounds to the clinic.
A single receptor found to mediate allergic drug reactions could lead to an antidote and allow compounds to be screened out early during drug discovery.
A new strategy that homes in on major nodes of cancer pathways offers a faster and more informative way to find mutations that cause drug resistance than the standard needle-in-haystack approach.
Public funding saw none of the exuberance of the private sector in 2014, but NIH wants to use big data initiatives to stretch its use of funds
Two academic deals in immune modulation and cancer for Boehringer Ingelheim; predicting responders in AML; designer small molecules that act like antibodies.